HOUSTON -- A novel approach detects genetically abnormal cells in the blood of non-small cell lung cancer patients that match abnormalities found in tumor cells and increase in number with the severity of the disease, a research team led by scientists at The University of Texas MD Anderson Cancer Center report in the journal Clinical Cancer Research.
Lung cancer patients in the study also had many times the number of these circulating abnormal cells than study volunteers in a closely matched control group.
"We suspect additional research will show that these circulating abnormal cells are circulating non-small cell lung cancer cells," said study corresponding author Ruth Katz, M.D., professor in MD Anderson's Department of Pathology. "Blood tests for these circulating tumor cells could be used to diagnose lung cancer earlier, monitor response to therapy and detect residual disease in patients after treatment."
Katz and colleagues conducted what they believe to be the first study to use a technique called fluorescence in situ hybridization (FISH) to detect abnormal circulating cells that have aberrations found in non-small cell lung cancer. FISH detects and quantifies abnormal cells by using dye-labeled DNA probes of cell chromosomes that cause cells with the targeted genetic abnormalities to light up when viewed under a fluorescent microscope.
"We were surprised to find many more abnormal circulating cells in lung cancer patients compared with what had been seen previously using other techniques," Katz said.
The researchers used 12 biomarker probes that target aberrations previously connected to lung cancer to analyze 59 cases of non-small cell lung cancer and 24 controls, people without lung cancer, including smokers and non-smokers. Their findings include:
Some biomarkers were associated with lung cancer recurrence and overall survival, but none were statistically significant after adjusting for age, sex and disease stage. Larger clinical trials are needed to address these associations, Katz said.
The FISH analysis used by the team detected more circulating abnormal cells – by orders of magnitude – than existing methods that rely on immunomagnetic beads to attach to an antibody found on the surface of circulating cells that originate in an organ's epithelium. Epithelial tissue lines the surfaces and cavities of organs and 80 percent of all solid tumor cancers originate in the epithelium. Detection methods for circulating tumor cells have focused strictly on epithelial cells.
While the FISH analysis detected up to 45,000 abnormal cells per milliliter of blood, studies using the antibody-based epithelial method typically find fewer than 10 abnormal cells per milliliter.
Katz believes part of the difference is that FISH is not limited to epithelial cells, so it picks up mesenchymal cells, thought to be involved in the spread of primary cancer to other organs, stem cell precursor cells and a variety of other cell types in addition to epithelial cells.
"That's what differentiates this study from others, we use DNA probes through FISH to look at chromosomal changes in the cell nucleus, regardless of the cell's origin," Katz said.
Katz said future plans include studies with larger numbers of patients to validate that circulating abnormal cells are related to disease stage, relapse and survival. They also will evaluate epithelial, mesenchymal, stem cell and blood and lymphocyte markers, combined with FISH, to track down the origin of circulating abnormal cells and their associated traits.
Work is under way to develop a clinical test based on FISH.
This research was funded by grants and a Cancer Prevention Fellowship from the National Cancer Institute, by MD Anderson's Specialized Program of Research Excellence in Lung Cancer grant from the NCI and a grant from AstraZeneca.
Study co-authors from MD Anderson are Weigong He, Abha Khanna, Ricardo Fernandez, Tanweer M. Zaidi, Nancy Caraway, M.D., and Hua-Zhong Zhang of the Department of Pathology; Margaret Spitz, M.D., Carol Etzel, Ph.D., and Randa El-Zein, M.D., Ph.D. of the Department of Epidemiology; Stephen Swisher, M.D., Reza J. Mehran, M.D., and Jack Roth, M.D., of the Department of Thoracic and Cardiovascular Surgery; Carlos Jimenez, M.D., of the Department of Pulmonary Medicine; and Jeffrey Morris, Ph.D., of the department of Biostatistics. David Blowers, Ph.D., of AstraZeneca in Cheshire, UK; Matthew Krebs of Paterson Institute for Cancer Research in Manchester, UK, and Feng Jiang, M.D., Ph.D., of the University of Maryland School of Medicine.
The University of Texas M. D. Anderson Cancer Center and its researchers have filed patents on the technology and other intellectual property reported in these papers. If licensing or commercialization of such intellectual property occurs, the researchers and M. D. Anderson may be entitled to financial consideration, including royalties. M. D. Anderson manages these relationships in accordance with appropriate statutes, rules, regulations and policies.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 40 comprehensive cancer centers designated by the National Cancer Institute. For seven of the past nine years, including 2010, MD Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in U.S. News & World Report.
Get MD Anderson News Via RSS Follow MD Anderson News on Twitter
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.